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The  use  of genetic  markers  as instrumental  variables  (IV) is  receiving  increasing  attention  from
economists,  statisticians,  epidemiologists  and  social  scientists.  Although  IV  is  commonly  used  in  eco-
nomics,  the  appropriate  conditions  for  the  use  of  genetic  variants  as  instruments  have  not  been  well
deﬁned.  The  increasing  availability  of biomedical  data,  however,  makes  understanding  of these  condi-
tions crucial  to the  successful  use of genotypes  as  instruments.  We  combine  the econometric  IV literature
with  that  from  genetic  epidemiology,  and  discuss  the biological  conditions  and  IV  assumptions  within  the
statistical  potential  outcomes  framework.  We  review  this  in  the  context  of  two  illustrative  applications.enetic variants
nstrumental variables
endelian randomization
otential outcomes
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. Introduction
Many studies in the social and epidemiological sciences aim
o make causal inferences using observational data. This is often
roblematic, as observed associations are not necessarily causal,
ith confounding being an important concern. Randomization
f treatment, as in a Randomized Controlled Trial (RCT), is
ne way to infer causality. However, such experiments are not
lways possible or feasible. An approach commonly used in the
conomics and econometrics literature is that of Instrumental
ariables (IV). This introduces a third variable (the instrument)
hat is robustly associated with the risk factor of interest, but
ot with the outcome variable, other than through its effect
n the risk factor. This instrument can then be exploited to
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entioned in these acknowledgements.
ttp://dx.doi.org/10.1016/j.jhealeco.2015.10.007
167-6296/© 2015 The Authors. Published by Elsevier B.V. This is an open access article umake causal inferences about the effect of the risk factor on the
outcome.
Recently, epidemiologists, statisticians, economists and other
social scientists have become interested in using genetic variants
as instruments. ‘Mendelian randomization’ refers to the random
assignment of an individual’s genotype at conception (Davey
Smith and Ebrahim, 2003; Davey Smith, 2007). Under certain
assumptions that we discuss in detail below, observed associations
between genetic variants and the outcome of interest are unlikely
to be due to confounding by behavioural or environmental fac-
tors. Mendelian randomization can therefore be exploited to make
causal inferences about the effects of modiﬁable (non-genetic)
risk factors, on different outcomes1. Statisticians have highlighted
some of the implicit statistical assumptions commonly made in
Mendelian randomization studies (e.g. Didelez and Sheehan, 2007;
Didelez et al., 2010). Genetic epidemiologists emphasize the impor-
tance of carefully examining the conditions that need to be met  for
genetic variants to be used as instruments (see e.g. Davey Smith
and Ebrahim, 2003; Sheehan et al., 2008; Lawlor et al., 2008a,b).
However, while studies in economics commonly use IV methods,
the (biological) conditions relevant for Mendelian randomiza-
tion have not been disseminated widely in this literature. The
increasing availability of biomedical information in social science
1 Appendix A provides a brief guide to the terms used in genetic studies.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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randomization) is likely to be related to the outcome through char-
acteristics such as social class, income, diet, etc.
There are many cases, however, where RCTs are infeasible (for
example, there may  be no effective intervention to randomize, such32 S. von Hinke et al. / Journal of H
atasets, however, makes understanding them crucial to the suc-
essful use of genotypes as instruments for modiﬁable risk factors.
The contribution of this paper is to discuss these conditions
ithin the well-known statistical potential outcomes framework.
e use the work by Imbens and Angrist (1994), Angrist et al. (1996),
nd Angrist et al. (2000), among others, which has been of great
mportance in linking the econometric IV literature to the poten-
ial outcomes framework. We link Mendelian randomization to
his framework, and discuss how the conditions, deﬁned in genetic
pidemiology, relate to the IV assumptions used in statistics and
conomics. To communicate best practice in genetic epidemiol-
gy to a wider economics audience, we review these conditions
n the context of two illustrative applications: one in social science
nd one in medicine. Speciﬁcally, we examine whether child fat
asscausally affects (1) academic achievement, and (2) blood pres-
ure, using 32 recently identiﬁed genetic variants as instrumental
ariables for fat mass.
These examples are pertinent for several reasons. For our social
cience application for example, obese children are more likely to
e absent from school, have sleep disorders, and be treated differ-
ntly by teachers, parents and peers. All these may  affect children’s
learning) environment and educational outcomes. However, an
bserved association between fat mass and academic achievement
s not necessarily causal. There are likely to be many confounders,
nd one can never be sure that all relevant ones are accounted
or. For our medical application, there is evidence that even rela-
ively small reductions in weight can reduce blood pressure and
ypertension risk (Neter et al., 2003). However, the increase in
besity in recent decades has been accompanied by a decrease
n hypertension, leading to questions about their association, with
ome suggesting that randomized controlled trials of weight reduc-
ion could have affected blood pressure through mechanisms other
han weight loss (Campos et al., 2006). The use of ordinary least
quares (OLS) suggests that fat mass is inversely related to edu-
ational attainment, but increases the risk of hypertension. When
sing carefully selected genetic variants as instruments for fat mass,
e ﬁnd no evidence of a causal relationship between fat mass and
cademic performance, although the parameters are imprecisely
stimated. In contrast, we ﬁnd a positive effect of fat mass on blood
ressure, suggesting that reductions in fat mass will reduce the risk
f cardiovascular disease.
Although Mendelian randomization is widely used in the med-
cal and epidemiological sciences, with its ﬁndings being fed into
harmacotherapeutic development, it is very controversial within
conomics. This mainly stems from the credibility of the ‘exclu-
ion restriction’: the assumption that the variants do not directly
ffect the outcome of interest. Indeed, there are many situations
hat may  violate this assumption, invalidating the instruments
nd biasing the estimates. One of the issues is that we have
ery limited knowledge and understanding of the speciﬁc func-
ions of genes, and studies that directly examine gene-function
re often underpowered. Hence, we can never be certain that the
xclusion restriction is satisﬁed. We  discuss this in detail, and
ighlight the speciﬁc (biological) pathways through which the use
f genetic variants as instrumental variables may  lead to invalid
nferences, including the potential for variants to have multiple
unctions, or to be correlated to other variants that affect the out-
ome of interest. We  also consider the implications of gene–gene
nd gene–environment interactions for Mendelian randomization.
inally, it is worth noting that the uncertainty of the exclusion
estriction is not speciﬁc to Mendelian randomization. Indeed, any
V analysis relies on this untestable assumption, and one gener-
lly assesses such studies based on whether the available evidence
uggests that the assumption is likely to hold (see also von Hinke
t al., 2012). We  discuss different ways of exploring its validity indi-
ectly in the context of Mendelian randomization and attempt toEconomics 45 (2016) 131–148
clearly articulate the potential situations that would invalidate the
approach2.
Section 2 details the conditions that need to be met for genetic
variants to be used as instruments. Section 3 introduces our empir-
ical application. We  describe the data, examine the validity of our
choice of genetic variants, present the results as well asa number of
sensitivity checks. Section 4 concludes and discusses the implica-
tions of our ﬁndings in terms of best practice for using Mendelian
randomization by researchers who  do not come from a primarily
biological discipline.
2. The use of genetic variants as instrumental variables
We  start by discussing the links between Mendelian randomiza-
tion and other approaches used in the medical and social science
literature. We  then build on the Potential Outcomes Framework by
Imbens and Angrist (1994), Angrist and Imbens (1995), Angrist et al.
(1996, 2000). We  ﬁrst brieﬂy outline the well-known structural
assumptions in the context of our applications, and then discuss
how Mendelian randomization links to the statistical assumptions
of this framework.
2.1. Mendelian randomization
We  discuss Mendelian randomization from a statistics and eco-
nomics perspective in the context of a social study, with the aim
of making causal inferences about the effect of a treatment on
an outcome of interest. Depending on the discipline, the terms
‘treatment’, ‘risk factor’, ‘exposure’, ‘predictor’, or ‘intermediate
phenotype’ have all been used to denote the variable of interest that
potentially causes the outcome. To avoid confusion, the remainder
of this paper uses either the term ‘treatment’ or ‘risk factor’.
The concept of Mendelian randomization is closely linked to
Randomized Controlled Trials (RCTs), where the allocation of treat-
ment is randomized over all eligible individuals (Davey Smith and
Ebrahim, 2005; Hingorani and Humphries, 2005). Indeed, IV can be
applied to analyse encouragement designs (such as RCTs where the
instrument is the encouragement to participate) that are affected
by non-ignorable non-compliance. Non-compliance refers to the
fact that individuals can choose to take or not take treatments
other than those to which they are randomized. Non-ignorable non-
compliance refers to participants choosing to take or not to take
the treatment that they are randomized to in a manner associated
with their study outcomes, after adjusting for baseline characteris-
tics. This is also known as endogenous treatment in economics, or
selection into treatment.
The idea is similar for the social context in our application:
individuals ‘select’ their treatment – fat mass – through lifestyle
choices, such as diet and physical activity, which are likely to
be related to their study outcome (educational attainment and
blood pressure). In a well-conducted RCT of an intervention aimed
at reducing fat mass, the random allocation effectively balances
these lifestyle choices between groups. Comparing groups based
on the original random allocation (‘intention to treat’) maintains
this balance, whereas comparing groups based on what treatment
was actually chosen by the participant (a ‘per-protocol’ analy-
sis) is likely to be biased due to non-ignorable non-compliance.
In other words, treatment by choice (as opposed to treatment by2 Thus we give below examples of situations where the use of genetic variants as
instrumental variables is more as well as less likely to lead to incorrect inference.
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s for adiposity) or unethical (for example, when examining the
ffect of prenatal alcohol consumption on different outcomes). In
uch cases, quasi-experimental designs such as Mendelian random-
zation experiments can provide a useful alternative approach.
As in RCTs, Mendelian randomization assumes that character-
stics such as social class, income and diet are balanced across the
enotypes. This assumption exploits the fact that there is an equal
robability that either parental allele (see Appendix A) is transmit-
ed to offspring. As this allocation is random at the family trio level,
he cleanest experiment is one with biological siblings, examining
andomization of genes within families (Davey Smith and Ebrahim,
003). However, also at a population level, many studies suggest
hat genetic variants are largely unrelated to the many socioeco-
omic and behavioural characteristics that are closely linked with
ach other and that confound conventional observational studies
Bhatti et al., 2005; Davey Smith et al., 2008; Kivimäki et al., 2008;
awlor et al., 2008a,b; von Hinke et al., 2014; see also Fisher, 1952;
ox 2010). Hence, as genes are randomly assigned during meiosis
cell division for reproduction), individuals of different genotypes
re expected not to differ systematically in any other respect. The
ssue of compliance in Mendelian randomization studies is dis-
ussed further in Section 2.2.
Interventional studies such as RCTs, where treatment is
ntroduced at a certain age, identify the effect of differences in
reatment from that point in time. By contrast, estimates from
endelian randomization experiments exploit differences in treat-
ent throughout life, estimating the long term (cumulative) effects
f the treatment on the outcome of interest (Davey Smith and
brahim, 2005).
As noted by Didelez and Sheehan (2007), the potential limita-
ions of Mendelian randomization studiesfall into two sets. First,
imitations related to the implicit statistical assumptions common
n many Mendelian randomization studies, such as linearity and
dditivity. As these have been discussed in detail (e.g. Didelez and
heehan, 2007; Didelez et al., 2010), we focus on the second set of
imitations: those relating to the assumptions of the validity of the
nstrument. Genetic epidemiology studies emphasize the impor-
ance of carefully examining several situations and (biological)
rocesses that may  violate the IV assumptions (see e.g. Davey Smith
nd Ebrahim, 2003; Sheehan et al., 2008; Lawlor et al., 2008a,b). The
ncreasing availability of biomedical information in social science
atasets makes understanding of these conditions crucial to the
uccessful use of genotypes as instruments for modiﬁable risk fac-
ors. We  therefore ﬁrst outline the structural assumptions in the
ontext of our applications, discuss the concepts deﬁned in epi-
emiology and relate them to the assumptions that need to be
et  to obtain causal estimates of the effect of the risk factor on
he outcome of interest, as deﬁned in the statistics and economics
iterature.
.2. The potential outcomes framework
Our two illustrative applications use a continuous treatment
nd outcome variable, and 32 independent genetic variants.
or ease of exposition, however, we discuss our framework for
he case of two genetic variants, though we  note that this is
asily generalized to incorporate any number of variants. As
hown in Angrist et al. (2000), with such discrete instruments,
he number of instruments is irrelevant; it is the number of
istinct values of the instrument vector that matters. Hence,
ith two genetic variants (denoted by Z1 and Z2), we observe
ine instrumental values, deﬁned by the combination of the
umber of rare alleles. Without loss of generality, we order
he instruments by their mean fat mass, for example: (Z1, Z2){
(0, 0) , (0, 1) , (1, 0) , (0, 2) (1, 1) , (1, 2) , (2, 0) , (2, 1) , (2, 2)
}
.
e can represent this as an instrument Z with support 1,2,. . .,9;Economics 45 (2016) 131–148 133
the full set of instruments are the nine mutually exclusive
dummy  variables. Let A and Y denote random variables repre-
senting, respectively, fat mass and the educational outcome/blood
pressure.
Let Ai (z) be the potential fat mass for individual i when the
instrument is set to z. Only one of the 9 possible treatment
assignments Ai (1) , Ai (2) , . . .,  Ai (9) is ever observed for any one
individual. Similarly, let Yi (z, a) be the potential outcome for indi-
vidual i that would be obtained if i‘s fat mass, the treatment variable,
was set to a and the instrument was  set to z. We  refer to Ai (z)
and Yi (z, a) as the potential treatments and potential outcomes
respectively. Similar to Ai (z), only one of the 9 potential outcomes
Yi (1, Ai (1)) , Yi (2, Ai (2)) , . . .,  Yi (9, Ai (9)) can ever be observed for
any one individual.
We follow convention and assume that individual i’s potential
treatments and potential outcomes are independent of the out-
come and treatment status of other individuals. This is also referred
to as the Stable Unit Treatment Value Assumption (SUTVA, see e.g.
Rubin, 1980).
Given the set of potential outcomes, we can deﬁne the
causal effects for individual i of Z on A as (Ai (z) − Ai (z − 1)),
and the causal effects for individual i of Z on Y as
(Yi (z, Ai (z)) − Yi (z − 1, Ai (z − 1))), for z ∈
{
2, . . .,  9
}
. These
are also known as the intention-to-treat effects.
Assumption 1 (Independence).
Zi⊥
{
Yi (z, a) , Ai (z)
}
z,a
The independence assumption implies that the instrument is
independent of all potential outcomes and potential treatments,
for all values of z and a. In other words, the instrument is as good
as randomly assigned. Note that, as Mendelian randomization is
closely related to RCTs, where the allocation of treatment is ran-
domized over all eligible individuals, we specify the unconditional
independence assumption. If the instruments are not independent
of covariates, however, we require the conditional independence
assumption, implying that independence holds conditional on
some vector of covariates, deﬁned by X. We  discuss the role of
covariates in Mendelian randomization studies in more detail in
Section 2.4.
Given SUTVA and independence, we can obtain unbiased esti-
mators for the average intention-to-treat effects by taking the
difference of sample averagesof the outcomes and treatments at
different values of the instrument.
Assumption 2 (Exclusion).
Yi (z, a) = Yi
(
z′, a
)
, for all z, z′ and for all a.
This implies that Yi (1, a) = Yi (2, a) = . . . = Yi (9, a), for all a,
or that the potential outcomes, at any level of fat mass a, are
unchanged by the value of the instrument. In other words, the only
way through which the instrument affects the potential outcome is
via A. It implies that Yi (z, a) is a function of a only, and hence we  can
write Yi (z, a) = Yi (a) . If the exclusion restriction only holds condi-
tional on X, we  can specify the exclusion restriction conditional on
these covariates.
With heterogeneous responses, the potential outcomes for indi-
vidual i can be written as a general function of a, say Yi (a) ≡ gi (a) .
We can deﬁne the individual causal effects of A on Y as the deriva-
tives of gi (a) . So the individual causal response is the difference in
potential outcomes at each value of a.Although we  can never observe any of these individual
causal effects, we can observe the average causal effects for
groups of individuals who  can be induced to change treatment:
E
[
g′
i (q) |Ai (z) < q < Ai (z′)
]
, where g′
i (q) is the derivative of gi (a)
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cases is beyond the scope of this paper, but for different approaches,
we refer the reader to Frangakis and Rubin (2002), Sjölander et al.
(2009), Jin and Rubin (2008), and Bartolucci and Grilli (2011).34 S. von Hinke et al. / Journal of H
.r.t. a evaluated at q. Inferences about such average causal effects
re made using changes in treatment status that are induced by the
nstrument (Angrist et al., 1996). For this, we require the instrument
o affect treatment status.
ssumption 3 (Non-zero effect of the instrument on treatment).[
Ai (z) − Ai
(
z′
)]
/= 0, for all z, z′
This implies that expected potential fat mass is affected by the
nstrument and therefore that the instrument has an effect on the
reatment.
ssumption 4 (Monotonicity).
P [Ai (z) ≥ Ai (z′)] = 1 for all z ≥ z′ or
P [Ai (z) ≤ Ai (z′)] = 1, for all z ≤ z′,
or all i. This implies that the potential fat mass for individual i with
nstrument value z is at least as high as the potential fat mass for
he same individual with instrument value z′, or vice versa, that the
otential fat mass for individual i with instrument value z is lower
han or equal to the potential fat mass for the same individual with
nstrument value z′, for all i.
We use the above assumptions to interpret differences in aver-
ge outcomes and treatments at different values of the instrument.
nder these assumptions, the IV estimand is equal to a weighted
verage of the 8 linearly independent average causal responses
ACRs), deﬁned here as z,z−1:
z,z−1 =
E [Yi|Zi = z] − E [Yi|Zi = z − 1]
E [Ai|Zi = z] − E [Ai|Zi = z − 1]
=
∫
E
[
g′i (q) |Ai (z − 1) < q < Ai (z)
]
P
{
Ai (z − 1) < q < Ai (z)
}
dq
∫
P
{
Ai (z − 1) < q < Ai (z)
}
dq
,
for z = 2, . . .,  9.
In other words, each instrumental variable identiﬁes a unique
ausal parameter, one speciﬁc to the subpopulation whose treat-
ent is affected by the instrument. Different valid instruments may
hereforelead to different causal parameters. Hence, IV estimation
hat uses each of the instruments one by one weights the deriva-
ive function g′
i (q) by the strength of the instrument (Angrist et al.,
000; Angrist and Pischke, 2009). Let the points of support of Z be
rdered such that l < m implies that E [Ai|Zi = l] < E [Ai|Zi = m] .  The
V estimand using all 9 mutually exclusive instruments can then be
ritten as:
9
z=2
ωzz,z−1 (1)
here
z = (E [Ai|Zi = z] − E [Ai|Zi = z − 1])
·
∑9
l=zl (E [Ai|Zi = l] − E [Ai])∑9
l=1lE [Ai|Zi = l] (E [Ai|Zi = l] − E [Ai])
nd l = Pr [Z = l], ωz > 0 and
∑
zωz = 1. Hence, it averages the
pairwise) instrument-speciﬁc weighted averages of the derivative
unction, where the weights are proportional to the instrument-
nduced change in the cumulative distribution function (CDF) of
at mass (Angrist and Imbens, 1995; Angrist et al., 2000; Angrist
nd Pischke, 2009). In other words, it combines a set of weighted
verage effects into a new weighted average.
The above example is for a case with two genetic variants, or
ine instrumental variables, which is straightforward to estimateEconomics 45 (2016) 131–148
in standard software packages. As discussed earlier, however, we
observe 32 genetic variants, and with that, a maximum of 332
instrumental variables3. Instead of specifying a model with that
many instruments, we  use one ‘allelic score’, mapping the instru-
mental variables z = 1, . . .,  332 onto a function h (Zi) , deﬁned as the
number of risk alleles carried by each child. In other words, for every
individual, we  sum the number of adiposity-increasing alleles for
the 32 variants. For example, the allelic score for the above case of
9 instruments takes ﬁve values:
(Z1, Z2) h (Zi)
(0, 0) 0
(0, 1) , (1, 0) 1
(1, 1) , (0, 2) , (2, 0) 2
(1, 2) , (2, 1) 3
(2, 2) 4
(in our sample, the allelic score using the 32 genetic variants
takes one of 28 distinct values, see also Section 3.4). Using the allelic
score h (Zi),  the IV estimand can be written as:
Cov (Yi, h (Zi))
Cov (Ai, h (Zi))
.
Similar to (1), the IV estimand that uses the multivalued allelic
score h (Zi) is a weighted average of the ACRs z,z−1. However, the
weights are now given by:
ωz =
(E [Ai|Zi = z] − E [Ai|Zi = z − 1]) ·
∑9
l=zl (h (Zi = l) − E [h (Zi)])∑9
m=1 (E [Ai|Zi = m] − E [Ai|Zi = m − 1]) ·
∑9
l=ml (h (Zi = l) − E [h (Zi)])
,
where, again, l = Pr [Z = l], ωz > 0 and
∑
zωz = 1 As above, the
weights are proportional to the ﬁrst stage impact on the treat-
ment (Angrist et al., 2000). Thus, inferences about the ACRs are
made using changes in treatment status that are induced by the
instrument.
At this point, it may  be useful to consider a situation where the
instrument and treatment are binary, in which case we can strat-
ify individuals into four latent groups, as commonly used in the
econometrics literature (e.g. Angrist et al., 1996): those who are
induced to take treatment by the instrument (compliers), those who
do the opposite of their assignment (deﬁers), those who never take
treatment, whatever their assignment (never-takers), and those
who always take treatment, regardless of their assignment (always-
takers).  In this framework, the IV estimate can be interpreted as a
Local Average Treatment Effect (LATE) or Complier Average Causal
Effect (CACE): the effect of treatment for those who  are induced to
take treatmentby the instrument (the compliers). Indeed, LATE or
CACE is not informative about effects on never-and always-takers,
because (by deﬁnition) treatment status for these groups is not
affected by the instrument. By virtue of the exclusion restriction,
the causal effect of Z on Y for never-takers and always-takers is zero.
And by virtue of the monotonicity assumption, there are no deﬁers.
Note that in the case of a continuous intermediate variable as gen-
erally used in Mendelian randomization studies (such as fat mass,
lipids, energy intake, units of alcohol, number of cigarettes, etc.), it
is unclear what it means to be a complier, deﬁer, always-taker, or
never-taker. A detailed discussion on identifying compliers in such3 Note that not all combinations of rare alleles may  be observed in the data, reduc-
ing  the total number of instruments. In addition, when multiple pairs of risk alleles
give the same predicted treatment, one may  condense the number of instrument
values, leading to a further reduction in the total number of instruments (see Clarke
et  al., 2015).
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.3. Conditions for the use of genetic variants as instrumental
ariables
For a valid causal interpretation of the IV estimand that uses
he genetic variants as instruments, we require the above assump-
ions to hold. However, there are various situations that may  violate
hem, which need to be examined. We  discuss these below.
ssumption 1 (Independence). Although genotypes are randomly
llocated at conception, the allele distribution may  differ for
ifferent population subgroups. If these subgroups also have sys-
ematically different outcomes of interest, this could lead to an
ssociation between the two at the population level without an
ctual causal relationship. A systematic relationship between the
llele frequency and the outcome of interest across different sub-
opulations is also referred to as ‘population stratiﬁcation’. For
xample, allele frequencies can vary across ethnic groups. Any
ystematic differences in the outcome of interest across these
ubpopulations that are not due to the genetic make-up may
herefore lead to biased estimates of the effect of treatment by
iolating the independence Assumption 1. In other words, despite
he fact that genotypes are randomly allocated and with that sat-
sfy independence, any population stratiﬁcation can violate this
ssumption. This can be dealt with, however, by examining the
uestion of interest within ethnic groups, separately analyzing the
ifferent subpopulations, and/or adjusting for principal compo-
ents from genome wide data that function as ancestry markers.
hese approaches then relyon the conditional independence
ssumption, assuming independence conditional on ethnicity or
ncestry.
As genotypes are randomly assigned given the parental genes,
he presence of assortative mating based on genes can violate
ndependence. The cleanest experiment, therefore, is one with
iological siblings, examining randomization of genes within fam-
lies (Davey Smith and Ebrahim, 2003). However, even when we
nly observe one individual per family, Mendelian randomiza-
ion is valid if we are able to assume that, at the population
evel, genetic variants are unrelated to other characteristics that
ay  affect the outcome of interest, as shown in many studies
Bhatti et al., 2005; Davey Smith et al., 2008; Kivimäki et al.,
008; Lawlor et al., 2008a,b; von Hinke et al., 2014; see also
isher, 1952). One way to indirectly test independence is by explor-
ng whether the distribution of observable characteristics is the
ame in different groups deﬁned by the value of the instrument
i.e. different genotypes). Indeed, if the instrument is random-
zed, there should be no systematic variation in the covariates by
enotype, whether we use a within- or between-family analysis.
his raises the question however, about which covariates to test
or, as any characteristic is, in principle, a post-treatment variable
ith respect to the instrument. Hence, any systematic variation
n these indirect tests does not necessarily indicate a violation
f independence (see also Rubin, 2005). It may  be, for example,
hat the instrument is picking up other causal effects of the same
reatment.
ssumption 2 (Exclusion).  One can never directly test whether
xclusion holds, and there are various situations in which Assump-
ion 2 fails, invalidating the instruments. One such situation is that
behaviours’ may  be affected by the genotype. As individuals inherit
heir genes from their parents, it may  be important to consider
hether parents’ behaviours or preferences are affected by their
enotype (and hence their offspring’s genotype). This can bias stud-
es that examine maternal behaviours that inﬂuence the outcome
f interest via intrauterine effects. Likewise, it may  be a problem
n studies where parental behaviours inﬂuence the outcomevia
ffecting their (child’s) behaviour.Economics 45 (2016) 131–148 135
As an example of the former, if one were interested in the
effect of an individual’s alcohol consumption on their later life
liver disease using a genetic variant that robustly relates to alcohol
intake, any intrauterine effects of maternal alcohol consumption
during pregnancy on offspring liver development could violate
Assumption 2. This is because the mother’s genotype is related to
the offspring’s genotype (the instrument), and will inﬂuence her
alcohol consumption throughout life, including potentially when
she was  pregnant. If maternal alcohol intake during pregnancy
affects her offspring’s liver development in utero and its functioning
later in the child’s life, there is a link from the offspring’s geno-
type (IV) to the outcome (the offspring’s liver disease) via maternal
genotype and maternal alcohol consumption, violating Assumption
2.
As an example of the latter, if one is interested in the effect of
fat mass on education, as we are below, parents who carry ‘fat’
alleles may  be discriminated against in the labour market because
of their on average higher weights (Cawley, 2004). If this affects
their behaviour or preferences for their child’s weight or education,
Assumption 2 may  be violated.
A second situation relates to the mechanisms through which
genetic variants affect the modiﬁable risk factor. These are often
unknown. If the mechanism involves changes in behaviour or pre-
ferences that in addition to affecting the risk factor also directly
affect the outcome, Assumption 2 will be violated. For example,
if the fat related genetic variants that we  use below inﬂuence fat
mass because they are related to pathways associated with addic-
tion more generally, such as addiction to high energy foods, and if
the latter affects the outcome of interest, Assumption 2 would be
violated. If the mechanism only results in changes to the risk factor
but does not directly affect the outcome, the exclusion restriction
is not violated.
Thirdly, the genetic instrument may  be related to other genetic
variants that affect the outcome of interest. Mendel’s second law
states that the inheritance of one trait is independent of the inher-
itance of another. However, it has been shown that this does not
always hold and that some variants are likely to be co-inherited.
This so-called ‘Linkage Disequilibrium’ (LD) does not occur for
genetic variants on different (non-homologous) chromosomes, and
the degree of LD is partly a function of the distance between the
loci (see Appendix A for some of the genetic terms used here).
Depending on the effects of the co-inherited variant, LD can bias
the estimates. If our instrument is in LD with another polymorphic
locus that affects only the modiﬁable risk factor, the IV estimates
remain consistent. However, if it is in LD with a polymorphic locus
that directly affects the outcome, Assumption 2 is violated. Relat-
edly, there is the situation of ‘pleiotropy’, where one genetic variant
has multiple functions. The case is similar to that of LD, and will
invalidate the IV approach if the pleiotropic effect inﬂuences the
outcome directly, but not if it affects only other characteristics that
are unrelated to the outcome of interest.
Fourth, a biological process that may  bias causal estimates in
Mendelian randomization studies is ‘canalization’. This refers to
the reduced sensitivity of a phenotype to the changes in underly-
ing genetic and non-genetic factors that determine its expression.
Hence, a canalized genotype produces the same (or a similar) phe-
notype in different genetic and non-genetic backgrounds (Flatt,
2005). For example, an individual who has a genetic variant asso-
ciated with higher blood pressure may not experience adverse
phenotypic effects of high blood pressure due to the arteries becom-
ing resistant. This is difﬁcult to test for, as the genetic variant may
still be related to blood pressure, but any adverse health outcomes
(phenotypes) normally caused by higher blood pressure would not
occur. Hence, canalization implies that the genotype can affect
the outcome through alternative channels, altering the associa-
tion between genotype and outcome, without any change in the
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enotype-risk factor relationship. Canalization, therefore, canvio-
ate the exclusion restriction.
These different potential violations of Assumption 2 indicate
hat, as the speciﬁc functions of genetic variants and the mecha-
isms through which they affect individuals are often unknown,
ne can never claim that exclusion holds. Indeed, one can only test
xclusion indirectly; we discuss this in more detail in Section 2.5
elow.
ssumption 3 (Non-zero effect of the instrument on treatment).  A
alid instrument must be associated with (i.e. have a non-zero
ffect on) the risk factor of interest. Mendelian randomization
an only be used with genetic variants that have been robustly
hown to affect the risk factor. This point is especially important,
s many initial genotype-risk factor associations fail to replicate
Colhoun et al., 2003). Without a consistent population associa-
ion, even if a sample correlation exists, Assumption 3 may  be
iolated. Indeed, choosing SNPs merely based on the sample asso-
iation with the risk factor (rather than using information external
o the study) can lead to biased IV estimates (Taylor et al., 2014).
t is therefore important that Mendelian randomization studies
nly use genetic variants that have been shown to be robustly
ssociated with the risk factor in a large number of independent
tudies.
However, even if a suitable genetic instrument is available, it
ay  explain little of the variation in the observed risk factor. A
eak association could result in a biased IV estimate and has impli-
ations for statistical power. If the alleles shift the distribution of
isk factor by a very small amount, the effect of the risk factor on
he outcome is identiﬁed only by this small difference, emphasiz-
ng the need either for very large sample sizes, especially when the
verage causal effect of the risk factor on the outcome could be
mall, or many genetic variants that can be combined into a more
owerful instrument. This, of course, is not a problem speciﬁc to
endelian randomization, but refers to a more general problem of
eak instruments (see e.g. Bound et al., 1995; Staiger and Stock,
997; Stock et al., 2002).
ssumption 4 (Monotonicity).  Whether monotonicity is satisﬁed
elies on knowing each individual’s counterfactual and therefore
lways remains an assumption. Monotonicity may  be violated
n the presence of gene–environment interactions; i.e. when the
ffect of the environment on the risk factor differs depend-
ng on individuals’ genetic predisposition, or when individuals’
enetic predispositions are expressed differently in different envi-
onments. For example, if the expression of a genetic variant
hat increases fat mass depends on individuals’ awareness of the
mportance of nutrition for one’s health, monotonicity may  be
iolated when the potential fat mass of an individual with the
enetic variant in an (e.g. educated) environment is less than the
otential fat mass for the same individual in that environment
ithout the genetic variant. However, if the expression of the
ariant is simply reduced in the educated environment, mono-
onicity would not be violated, as the potential adiposity of an
ndividual with the genetic variant remains at least as high as the
otential adiposity for the same individual without the genetic
ariant.
.4. The role of covariates in mendelian randomization
xperiments
There is a large literature on the use of covariates in IV. Eco-
omics and social applications of IV generally include a wide set of
ontrol variables; the main motivation being that the conditional
ndependence and exclusion restriction are more likely to be valid.
 second reason for including covariates in many economics andEconomics 45 (2016) 131–148
social applications of IV is that it may  reduce the residual variability
of the dependent variable, leading to more precise estimates.
The situation is somewhat different, however, in RCTs/
encouragement designs, and in Mendelian randomization stud-
ies. When covariates enter the assignment mechanism in
RCTs/encouragement designs, such as when randomization takes
place within certain strata, these covariates should be controlled
for, relying on the conditional independence assumption. The inclu-
sion of further baseline covariates may  in addition increase the
precision of the estimates. In Mendelian randomization stud-
ies, however, there are no baseline covariates. Furthermore, as
covariates do not enter the assignment mechanism, assignment
is independent of covariates, and we can rely on the uncon-
ditional independence assumption. Therefore, conditioning on
covariates is not necessary in Mendelian randomization exper-
iments. The exception, however, is when there is population
stratiﬁcation. In this case, the analyses should be done within
population subgroups, or should adjust for principal components
from genome wide data, relying on the conditional independence
assumption.
Although one may  choose to adjust for covariates to increase
precision, this raises the issue of which covariates to include in a
Mendelian randomization study, as any characteristic is, in prin-
ciple, a post-treatment variable with respect to the instrument,
and – with that – may  be affected by the instrument. If the instru-
mented treatment has multiple causal effects, or if the outcome
has a causal effect of its own, adjusting for such post-treatment
variables may  lead to biased estimates of the causal effect. Indeed,
we should not control for any ‘downstream’ (behavioural) covari-
ates that are potentially affected by the treatment or outcome.
Thus, we  only control for 10 ancestry-informative principal com-
ponents in our main analyses, though we report the estimates
that adjust for further covariates in the sensitivity analysis. Under
independence, and when the instrumented treatment and out-
come do not affect these covariates, the unadjusted and adjusted
IV estimates should be similar, though the latter may be more
precise.
2.5. Testing the exclusion restriction
There is no direct test for the validity of the exclusion restriction
(Assumption 2). In other words, its validity will never be known
with certainty and can only be examined indirectly or falsiﬁed
by the data. To this end, however, Mendelian Randomization is
no different from any other (non-genetic) IV study; the exclusion
restriction always remains an assumption. However, one of the dif-
ferences, one may  argue, is that the speciﬁc functions of genetic
variants and the mechanisms through which they affect individuals
are often unknown, making it more difﬁcult, if not impossible, to
argue that the instrument is valid. However, with a rapidly grow-
ing medical literature, our knowledge on the speciﬁc function of
variants is increasing. For example, much is now known about the
function of certain variants in the metabolism of alcohol, leading
to clear predictions from the medical literature on how they affect
individuals’ alcohol consumption. But knowing the exact function
of a variant is not sufﬁcient. Indeed, the variant may be pleiotropic,
and its pleiotropic effects may have not yet have been identiﬁed,
potentially invalidating the instrument.
Similar to other IV studies that use multiple instruments, how-
ever, Mendelian randomization allows for potential violations
through pleiotropy or LD (though not necessarily canalization) to
be tested when data is available on a large number of genetic
instruments. More speciﬁcally, if multiple IV models – each using
different combinations of these variants – predict the same causal
effect, it is unlikely to be due to some common pleiotropy or LD
across the different sets of variants, assuming that the different
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educational records, in-depth interviews, and biological samples.
Note however, that ALSPAC is a cohort; as such, there is no system-
atic data collection on siblings.S. von Hinke et al. / Journal of H
ariants are located on different chromosomes and affect the trait
ia different pathways (Davey Smith, 2011; Palmer et al., 2011;
on Hinke et al., 2013). Hence, consistency between such estimates
rovides evidence against potential pleiotropy or LD-induced con-
ounding. However, obtaining different causal effects with different
ombinations of variants does not necessarily point to a violation
f the exclusion restriction, as variability in treatment effects may
ccur due to different compliant subpopulations for the different
nstrument sets (i.e. different LATEs or CACEs).
Alternatively, one can view Mendelian randomization with mul-
iple instruments as analogous to a meta-analysis of separate
tudy results. Just like the IV estimate using multiple instrumen-
al variables is a weighted average of the individual IV estimates,
 meta-analysis is a weighted average of multiple studies. Bowden
t al. (2015) show that, in this setting, Egger regression (a tool to
etect small study bias in meta-analysis) can be adapted to test
or bias from pleiotropy. In addition, it can provide an estimate of
he causal effect of the treatment on the outcome of interest, even
hen the genetic variants are invalid.
In a constant effects model, one can indirectly test whether the
xclusion restriction holds using an ‘over-identiﬁcation’ (Sargan or
ansen) test (Sargan, 1958; Hansen, 1982), provided that there are
ore instruments than endogenous variables. Note, however, that
his is not a test that the instruments are indeed valid. A problem
ith the over-identiﬁcation test is that it has low power, especially
hen the underlying IV estimates are imprecise. In our heteroge-
eous treatment effects framework however, over-identiﬁcation
ests are inappropriate, even when the underlying estimates are
recise, as a rejection of the test need not imply a violation of the
xclusion restriction. As discussed above, it may  point to treatment
ffect heterogeneity, as different valid instruments may  estimate
ifferent parameters, with the ﬁnal IV estimate being a weighted
verage of the different treatment effects. Hence, although we
eport the test statistic below, we cannot necessarily interpret it
n a heterogeneous treatment effects framework.
Note that, although canalization refers to a violation of the
xclusion restriction, it cannot necessarily be tested using over-
dentiﬁcation tests. Similar to the above, a rejection cannot
istinguish between treatment effect heterogeneity and canaliza-
ion. In fact, there is no (clear) way of testing or correcting for
analization. However, for the complex traits that are largely of
nterest in Mendelian randomization studies, there is no evidence
hat canalization occurs in humans (Davey Smith and Ebrahim,
003).
.6. Previous studies in the economics literature
The existing economics literature includes three studies that
xploit genetic variation to identify the effects of BMIon economic
utcomes. Ding et al. (2009) examine the effects of several health
onditions, one of which is BMI, on adolescents’ academic achieve-
ent. Their IV results show large and signiﬁcant negative effects on
irls’ Grade Point Average (GPA), but not for boys. GPAs for obese
irls are on average 0.8 points lower than for non-obese girls. They
se four genetic variants as instruments: the dopamine transporter
DAT1) and D2 receptor (DRD2), tryptophan hydroxylase (TPH) and
ytochrome P4502B6 (CYP2B6). Fletcher and Lehrer (2011) take a
imilar approach to Ding et al., but use the Add Health data to
xploit within-family genetic inheritance. They ﬁnd no evidence
hat obesity affects academic achievement. In addition to DAT1 and
RD2,  their instruments include the dopamine D4 receptor (DRD4),
he serotonin transporter (5HTT), monoamine oxidase (MAOA) and
ytochrome P4502A6 (CYP2A6). Finally, Norton and Han (2008)
xamine the effects of BMI  on labour market outcomes using DAT1
nd DRD4 as instruments for BMI  and ﬁnd no evidence of a causal
ssociation.Economics 45 (2016) 131–148 137
The discussion in Section 2.3 above highlights the importance of
the choice of genetic variants in Mendelian randomization experi-
ments. Although the validity of the exclusion restriction can never
be tested directly, it is unlikely that genes related to neurotrans-
mitters such as dopamine receptors and serotonin transporters are
valid instruments. The inherent problem is that neurotransmitters
are implicated in many different neurological processes. Hence, it is
difﬁcult to argue that they can be used as valid instruments for one
speciﬁc risk factor without being associated with others that could
plausibly inﬂuence the outcome of interest (Cawley et al., 2011;
von Hinke et al., 2011).
More generally, however, Mendelian randomization can only
be used with genetic variants that have been robustly shown to
affect the risk factor (Assumption 4), relying on prior knowledge
about the association between the genotype and risk factor. The
choice of instruments in the studies cited above, however, seems
to be data-derived: using either forward stepwise estimation (Ding
et al.) or selecting those SNPs that have nominally statistically sig-
niﬁcant sample correlations in the ﬁrst stage (Fletcher and Lehrer).
Furthermore, both Ding et al. and Fletcher and Lehrer acknowl-
edge that there is weak and inconsistent evidence in the medical
literature, based on very small unrepresentative clinical samples,
of the association between their genetic variants and health sta-
tus or behaviours. Indeed, the IV strategy is invalid when relying
only on such sample associationsand leads to biased results (Taylor
et al., 2014). Norton and Han (2008) base their selection of SNPs
on a study by Guo et al. (2006), who  ﬁnd a negative association
between the D4.7/D4.7 genotype of DRD4 and obesity. This rela-
tionship, however, has not been replicated in other independent
studies (see for example Hinney et al. (1999), or Fletcher and Lehrer
(2011) who ﬁnd an insigniﬁcant but positive association; see also
Lawlor et al., 2008a).
To our knowledge, there are no studies in economics that
explore the effects of BMI  on blood pressure. However, the relation-
ship has been explored in the medical literature. Indeed, Timpson
et al. (2009) use two genetic variants, FTO and MC4R, as instruments
for BMI  to explore the effects on blood pressure and hypertension
risk. Using those aged 20 and over from the Copenhagen General
Population Study, they ﬁnd that BMI  increases both systolic and
diastolic blood pressure. We  are, however, not aware of any studies
exploring this relationship for children or adolescents.
3. Application: The effect of fat mass on academic
performance and blood pressure
3.1. Data
Our data are from a cohort of children born in one geographic
area (Avon) of England. Women  eligible for enrolment in the
population-based Avon Longitudinal Study of Parents and Children
(ALSPAC) had an expected delivery date between 1 April 1991 and
31 December 1992. Approximately 85% of these mothers enrolled,
leading to about 14,000 pregnancies. The Avon area has approxi-
mately 1 million inhabitants and is broadly representative of the
UK as a whole, though slightly more afﬂuent than the general
population4. Detailed information on the study children and their
families has been collected using a variety of sources, including
self-completed questionnaires, data extraction from medical and4 For more information on the representativeness of ALSPAC, its enrolment and
response rates, see Boyd et al., 2012; Fraser et al., 2012; and www.bristol.ac.uk/
alspac.
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not likely to be a problem here, as our cohort is recruited from a
speciﬁc geographically deﬁned region with a predominantly white
population. In addition, our analysis only includes children whose
5 We discuss these in more detail below, as well as in the Web  Appendix. In
short, however, these are NRXN3 (rs10150332), BDNF (rs10767664), GNPDA2
(rs10938397), LRRN6C (rs10968576), PRKD1 (rs11847697), GPRC5B (rs12444979),
CADM2 (rs13078807), SLC39A8 (rs13107325), TNNI3K (rs1514175), PTBP2
(rs1555543), FTO (rs1558902), NUDT3 (rs206936), FLJ35779 (rs2112347), MAP2K5
(rs2241423), QPCTL (rs2287019), NEGR1 (rs2815752), TMEM18 (rs2867125), LRP1B38 S. von Hinke et al. / Journal of H
A total of 12,620 children survived past the age of 1 and returned
t least one questionnaire. Of these, we exclude 642 children
ecause either their mother or father is of non-white ethnic origin
to avoid potential population stratiﬁcation), leaving 11,978 poten-
ial participants. Our sample selection process is as follows. First,
e select children for whom we observe their genotypes and 10
ncestry-informative principal components, leaving us with 7335
hildren. Second, we drop children with missing data on fat mass.
e further restrict the sample to children for whom we observe
heir educational outcomes and blood pressure, leading to a ﬁnal
ample size of 4844 and 4047 children, respectively.
Attrition in the ALSPAC cohort is known to be correlated with
ocio-economic position, with children from lower educated, lower
ncome families more likely to drop out (Boyd et al., 2012; Fraser
t al., 2012). Attrition can bias our analyses if observations are lost
n a non-random manner. We  explore attrition more generally in
able 1. Column 1 shows the descriptive statistics for the full sam-
le of children for whom data is available. Column 2 shows the
tatistics for the sample with genetic information, and column 3
nd 4 use the ﬁnal estimation sample for educational outcomes
nd blood pressure respectively. We  conﬁrm the socio-economic
radient in attrition: children in the estimation sample do signiﬁ-
antly better in school, based on their Key Stage 3 (KS3) tests, their
amilies are wealthier than the original sample, of higher socio-
conomic position, and their mother are higher educated and older,
ith fewer mental health problems. Hence, there are considerable
ifferences in the distribution of observables between the original
nd estimation samples. Note, however, that we ﬁnd no evidence
f any selection or non-random attrition based on genetic variants,
hether we use an unweighted or weighted score, or the 32 indi-
idual variants. Furthermore, there are no signiﬁcant differences
n children’s blood pressure and fat mass between the different
amples. Hence, although our analyses may  be based on a selected
ample of individuals, potentially limiting its generalizability, any
ttrition is unrelated to the genotypes used here.
.2. Measures of academic achievement, blood pressure, fat mass,
nd the genetic variants
Our ﬁrst outcome measure is the child’s Key Stage 3 (KS3) score.
he KS3 exam is a nationally set exam, taken by all 14-year-olds
n English state schools. This measure of children’s performance is
herefore objective and comparable across all children. Their scores
or three subjects (English, maths and science) are obtained from
he National Pupil Database, a census of pupils in England in the
tate school system, which is matched into ALSPAC. We  use an aver-
ge score for the three subjects, standardized on the full sample
f children for whom data is available, with mean 100, standard
eviation 10.
Our second outcome measure is the child’s blood pressure, mea-
ured in millimetres of mercury (mmHg) at age 13. We  observe
oth systolic (maximum) and diastolic (minimum) blood pressure,
easured by trained nurses. Blood pressure was measured twice
t the clinic; we use the average of the two readings to reduce
easurement error.
Our main measure for child fat mass, our risk factor of interest,
s the child’s body fat mass (adjusted for age in months, height and
eight squared), as measured by a dual-energy X-ray absorptiome-
ry scan (DXA) at age 11. As fat mass is measured two to three years
rior to the outcomes of interest, this avoids potential problems
elated to reverse causation. The DXA scan scans the whole body,
ividing it into fat, lean tissue, and bone mass. We  standardize fat
ass on the full sample of children for whom data are available,
ith mean 100 and standard deviation 10.
For the genetic variants, we use 32 SNPs that have been con-
istently found to relate to body weight and fat mass (SpeliotesEconomics 45 (2016) 131–148
et al., 2010; see below)5. There are different ways to include these
instruments in our analyses, though each of these has poten-
tial drawbacks. For example, we may  use the 32 variants or the
64 adiposity-increasing alleles as separate instrumental variables,
potentially leading to weak instrument bias, as the effect of each
individual variant or allele on adiposity is small. Alternatively, we
could use a count of the total number of risk alleles carried by
each individual (an ‘allelic score’), increasing the strength of the
instruments. However, this imposes an equal effect size for every
allele, which is not necessarily supported by the data. Similarly, we
could deﬁne multiple instruments as separate dummy variables
indicating the number of risk alleles carried by each individual.
Although this allows for different numbers of risk alleles to have
different effect sizes, it assumes that the effect of carrying e.g. four
risk alleles is the same no matter which four they are. We  could
also use a weighted allelic score, where the weights are deﬁned by
the effect size of each particular variant on adiposity, as estimated
in an independent meta-analysis.
The evidence suggests that allele scores give unbiased esti-
mates and are more efﬁcient than using the individual variants.
There is some loss of power associated with an unweighted rather
than weighted score,with the extent of the loss depending on the
variation in effect sizes (see e.g. Pierce et al., 2010; Burgess and
Thompson, 2013; Davies et al., 2014). Furthermore, the evidence
suggests that the bias properties of the weighted and unweighted
scores are robust to mis-speciﬁcations of the score, such as the
presence of gene–gene and gene–environment interactions, and
the mis-measurement of weights in a weighted score approach
(Burgess and Thompson, 2015). In our main analysis, we use an
unweighted allelic score, increasing the power of the instruments
and alleviating weak IV problems. However, we also explore the
alternative speciﬁcations discussed above in the sensitivity analy-
ses.
3.3. Examining the validity of the genetic variants in our
empirical applications
Using a total of 249,796 individuals from 64 different cohorts of
European ancestry, Speliotes et al. (2010) conducted a large-scale
GWAS meta-analysis. This conﬁrmed 14 known obesity susceptibil-
ity loci and identiﬁed 18 new loci, with no evidence of non-additive
effects, SNP × SNP interaction effects, or heterogeneity by sex or
study. We  use these 32 variants to explain variation in adiposity.
We next relate the speciﬁc choice of these variants to the assump-
tions for suitable use of genetic variants as instruments discussed
in Sections 2.2 and 2.3.
Assumption 1 (Independence). The independence assumption
may  be violated in the presence of population stratiﬁcation due
to ethnicity. For example, the allele frequencies of the SNP that
accounts for the largest proportion of the variance (FTO) are known
to vary by ethnic group (Frayling et al., 2007). Nevertheless, it is(rs2890652), KCTD15 (rs29941), TMEM160 (rs3810291), MTCH2 (rs3817334),
MTIF3 (rs4771122), ZNF608 (rs4836133), RPL27A (rs4929949), SEC16B (rs543874),
MC4R (rs571312), RBJ (rs713586), FAIM2 (rs7138803), SH2B1 (rs7359397), FANCL
(rs887912), ETV5 (rs9816226), TFAP2B (rs987237), where the rs-number is an
identiﬁcation tag that uniquely positions the polymorphism in the genome.
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Table  1
Mean and standard deviation (SD) of adiposity for each SNP.
Original sample Genetic sample Estimation sample (KS3) Estimation sample (BP)
Outcomes Mean SD Mean SD Mean SD Mean SD
KS3 100 (10.0) 101*** (9.6) 103*** (8.9) 104*** (8.8)
Systolic BP 111 (11.5) 111 (11.3) 111 (11.2) 111 (11.2)
Diastolic BP 56.3 (8.39) 56.2 (8.28) 56.2 (8.28) 56.2 (8.28)
Treatments
Fat  mass 100 (10.0) 100 (9.8) 100 (9.8) 100 (9.7)
Instruments
Unweighted score 28.9 (3.47) 28.9 (3.5) 28.9 (3.45) 28.9 (3.44)
Weighted score 4.02 (0.53) 4.02 (0.53) 4.02 (0.53) 4.02 (0.53)
NRXN3 0.42 (0.57) 0.42 (0.57) 0.42 (0.58) 0.42 (0.57)
BDNF  1.59 (0.58) 1.59 (0.58) 1.59 (0.58) 1.60 (0.57)
GNPDA2 0.87 (0.70) 0.87 (0.70) 0.86 (0.69) 0.86 (0.69)
LRRN6C 0.63 (0.65) 0.63 (0.65) 0.63 (0.65) 0.63 (0.65)
PRKD1 0.09 (0.30) 0.09 (0.30) 0.09 (0.30) 0.10 (0.30)
GPRC5B 1.73 (0.49) 1.73 (0.49) 1.73 (0.49) 1.73 (0.49)
CADM2 0.40 (0.57) 0.40 (0.57) 0.40 (0.57) 0.40 (0.57)
SLC39A8 0.15 (0.37) 0.15 (0.37) 0.14 (0.36) 0.15 (0.37)
TNNI3K 0.85 (0.70) 0.85 (0.70) 0.85 (0.70) 0.85 (0.70)
PTBP2 1.18 (0.70) 1.18 (0.70) 1.18 (0.70) 1.19 (0.69)
FTO  0.81 (0.69) 0.81 (0.69) 0.81 (0.70) 0.82 (0.70)
NUDT3 0.39 (0.56) 0.39 (0.56) 0.39 (0.56) 0.39 (0.56)
FLJ35779 1.28 (0.67) 1.28 (0.67) 1.27 (0.67) 1.27 (0.67)
MAP2K5 1.57 (0.58) 1.57 (0.58) 1.57 (0.58) 1.57 (0.58)
QPCTL 1.62 (0.56) 1.62 (0.56) 1.62 (0.56) 1.62 (0.56)
NEGR1 1.20 (0.69) 1.20 (0.69) 1.19 (0.69) 1.18 (0.69)
TMEM18 1.66 (0.53) 1.66 (0.53) 1.66 (0.53) 1.66 (0.53)
LRP1B 0.34 (0.53) 0.34 (0.53) 0.34 (0.53) 0.33 (0.53)
KCTD15 1.37 (0.66) 1.37 (0.66) 1.37 (0.65) 1.38 (0.65)
TMEM160 1.39 (0.64) 1.39 (0.64) 1.38 (0.64) 1.39 (0.64)
MTCH2 0.80 (0.69) 0.80 (0.69) 0.80 (0.70) 0.80 (0.69)
MTIF3 0.46 (0.59) 0.46 (0.59) 0.46 (0.59) 0.47 (0.59)
ZNF608 0.99 (0.71) 0.99 (0.71) 0.99 (0.71) 0.99 (0.71)
RPL27A 1.08 (0.70) 1.08 (0.70) 1.09 (0.70) 1.10 (0.70)
SEC16B 0.42 (0.58) 0.42 (0.58) 0.42 (0.58) 0.42 (0.58)
MC4R 0.47 (0.60) 0.47 (0.60) 0.47 (0.60) 0.47 (0.60)
RBJ  0.98 (0.71) 0.98 (0.71) 0.98 (0.71) 0.98 (0.71)
FAIM2 0.72 (0.68) 0.72 (0.68) 0.72 (0.68) 0.72 (0.67)
SH2B1 0.83 (0.70) 0.83 (0.70) 0.82 (0.70) 0.82 (0.70)
FANCL 0.58 (0.65) 0.58 (0.65) 0.58 (0.64) 0.58 (0.65)
ETV5  1.65 (0.54) 1.65 (0.54) 1.65 (0.53) 1.66 (0.53)
TFAP2B 0.36 (0.54) 0.36 (0.54) 0.36 (0.54) 0.36 (0.54)
Covariates
Girl  0.48 (0.50) 0.49 (0.50) 0.51*** (0.50) 0.52*** (0.50)
Birth  weight 3404 (557.2) 3439*** (532.1) 3436*** (525.7) 3438*** (521.6)
Age  at KS3 (in months) 170 (3.73) 170 (3.77) 170 (3.68) 170 (3.71)
Ln  (income) 5.29 (0.49) 5.33*** (0.48) 5.35*** (0.46) 5.37*** (0.46)
Mother’s education
O-level 0.45 (0.50) 0.44 (0.50) 0.44 (0.50) 0.44* (0.50)
A-level 0.22 (0.42) 0.25*** (0.43) 0.26*** (0.44) 0.27*** (0.45)
University degree 0.12 (0.33) 0.15*** (0.35) 0.16*** (0.37) 0.17*** (0.38)
Not  natural father 0.92 (0.28) 0.93** (0.26) 0.93*** (0.25) 0.94*** (0.24)
Father’s social class ***
Managerial 0.34 (0.47) 0.36** (0.48) 0.36*** (0.48) 0.37 (0.48)
Non-manual skilled 0.12 (0.33) 0.12 (0.33) 0.13* (0.34) 0.13*** (0.34)
Manual skilled 0.31 (0.46) 0.29*** (0.45) 0.29 (0.45) 0.28*** (0.45)
Semi-skilled 0.10 (0.30) 0.09* (0.29) 0.08*** (0.27) 0.08*** (0.27)
Unskilled 0.03 (0.17) 0.02* (0.15) 0.02*** (0.14) 0.02*** (0.14)
Mum  works part-time 0.36 (0.48) 0.38* (0.48) 0.38*** (0.49) 0.39*** (0.49)
Mum  works full-time 0.10 (0.30) 0.11 (0.31) 0.11** (0.32) 0.11** (0.32)
Partner employed 0.88 (0.33) 0.89*** (0.31) 0.89 (0.32) 0.89 (0.32)
IMD  20.8 (14.9) 19.7*** (14.4) 18.7*** (13.7) 18.6*** (13.6)
Alcohol in pregnancy 0.55 (0.50) 0.56 (0.50) 0.57** (0.49) 0.58*** (0.49)
Smoke in pregnancy 0.24 (0.43) 0.21*** (0.41) 0.17*** (0.38) 0.16*** (0.37)
Breastfeed <1 month 0.16 (0.37) 0.16 (0.36) 0.16 (0.37) 0.15 (0.36)
Breastfeed 1–3 months 0.16 (0.36) 0.16 (0.36) 0.16 (0.37) 0.16 (0.37)
Breastfeed 4 + months 0.42 (0.49) 0.47*** (0.50) 0.50*** (0.50) 0.51*** (0.50)
Mother’s age: 20–24 0.18 (0.39) 0.16*** (0.37) 0.13*** (0.34) 0.13*** (0.33)
Mother’s age: 25–29 0.40 (0.49) 0.39 (0.49) 0.40 (0.49) 0.40 (0.49)
Mother’s age:30–34 0.28 (0.45) 0.31*** (0.46) 0.33*** (0.47) 0.34*** (0.47)
Mother’s age: 35+ 0.10 (0.30) 0.11** (0.31) 0.12*** (0.33) 0.12*** (0.33)
EPDS  score 6.88 (4.83) 6.68*** (4.69) 6.45*** (4.56) 6.34*** (4.51)
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Table 1 (Continued )
Original sample Genetic sample Estimation sample (KS3) Estimation sample (BP)
Outcomes Mean SD Mean SD Mean SD Mean SD
CCEI score 13.2 (7.78) 12.8*** (7.51) 12.6*** (7.31) 12.4*** (7.22)
Sample size 11,978 7335 4844 4047
Notes: Family income is an average of two observations (when the child is aged 3 and 4) and is in 1995 prices. It is adjusted for family size and composition (equalized)
using the OECD equivalence scale to allow for a comparison of incomes for all households. The social class variables use the standard UK classiﬁcation of social class based on
occupation (professional, managerial/technical, non-manual skilled, manual skilled, semi-skilled and unskilled). IMD  refers to the Index of Multiple Deprivation, and provides
a  relative measure of deprivation at small area level. EPDS and CCEI refer to the mother’s Edinburgh Postnatal Depression Score and the Crown-Crisp Experimental Index.
EPDS  indicates to what extent the mother is at risk of perinatal depression; CCEI captures a broader deﬁnition of mental health, measuring general anxiety, depression and
somaticism. Higher scores mean the mother is more affected. The descriptive statistics for the full sample, Column (1), are based on a maximum of 11,978 observations if
the  variable reported in the column has no missing values on any observations.
* p < 0.10,
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*** p < 0.01 refers to a test whether the mean is signiﬁcantly different from the mea
other describes herself and the child’s father as white, and we
djust all analyses for 10 ancestry-informative principal compo-
ents. Furthermore, we investigate whether there is any evidence
f systematic variation in the covariates by genotype. Appendix B
resents the results, exploring whether the distribution of covari-
tes is the same across the instrument distribution. Although there
re no true pre-randomization variables, and signiﬁcant differ-
nces do not necessarily indicate violation of independence (see
lso Section 2.3), we ﬁnd no evidence of systematic differences for
he different covariates, providing at least suggestive evidence of
andomization of the genetic variants.
ssumption 2 (Exclusion).  The exclusion restriction may  be vio-
ated in different situations. First, we note that those who carry the
diposity-increasing alleles of any of the variants used here do not
ecessarily become obese. The variants increase body weight by
 modest amount, with the majority of effect sizes below 500 g.
n addition, as individuals do not know their genotype, parents
re unlikely to notice the subtle difference in (children’s) size that
s related to their genotype. Hence, it is unlikely to observe any
trong responses to increased body weight, such as changing (chil-
ren’s) diets. However, the question remains whether there are
ny more subtle responses to higher body weights. As it requires
arge sample sizes and data on different parental preferences and
ehaviours to explore that in detail, one cannot say with complete
ertainty that behaviours are unaffected. Nevertheless, we  explore
his indirectly in our data, testing whether mothers’ behaviours or
haracteristics6 are related to their genotype. In the Web  Appendix,
able S1, we explore whether the distribution of covariates is the
ame in groups deﬁned by the mothers’ genotype, showing little
vidence of systematic differences. This may  be because there sim-
ly are no differences in maternal behaviours by genotype, because
e lack sufﬁcient power to detect any differences, or because we
o not observe the behaviours that are affected by the genotype.
Second, we searched for and examine existing literature related
o the mechanism through which the variants may  affect fat mass.
nfortunately, little is known about the physiological function
f most of our variants, with much of this work ongoing in the
edical literature. Nevertheless, there is evidence that some vari-
nts (FTO, MC4R)  are associated with an increased consumption
f fat and energy (see e.g. Timpson et al., 2008; Cecil et al., 2008;
ichmond and Timpson, 2012). The literature suggests that the
NPs increase food intake due to diminished satiety (Wardle et al.,
6 Including her education, age, lone parenthood, employment, smoking, drinking,
uration of breastfeeding, locus of control, a ‘teaching score’, and two  scores indi-
ating her engagement with and interest in outdoor, and in indoor activities with
he child.he original sample shown in Column 1.
2008), rather than through pathways that affect our outcomes of
interest. Table S2 in the Web  Appendix brieﬂy lists what the 32 vari-
ants used here have been shown to be associated with. Although
the vast majority of associations are with adiposity-related phen-
otypes, we note that the variants are likely to be associated with
additional phenotypes not shown in the Table, either because stud-
ies that have explored these associations were underpowered, or
because studies have not (yet) investigated those relationships.
Depending on these additional associations, they may  invalidate
their use as instruments if they affect the outcome of interest
directly. Nevertheless, our current knowledge suggests that, in
addition to being related to adiposity and adiposity-related phen-
otypes (such as Type II diabetes), some variants havebeen shown
to be associated with allergic asthma and rhinitis (rs10767664),
hyperactivity/impulsivity (rs1307880, rs2241423), schizophrenia
(rs10150332 and rs13107325), inattention (rs206936), white mat-
ter integrity (rs2815752), and Alzheimer disease risk (rs4836133,
rs713586)7. We  explore the robustness of our results to excluding
these variants from the instrument setin the sensitivity analyses
below.
Third, pleiotropy or LD would bias the IV estimates if the variant
affects the outcome directly or if the linkage is with another vari-
ant that directly affects our outcomes of interest. We  explore maps
of the human genome to investigate LD, and ﬁnd no evidence that
the variants used here directly affect (or are in LD with variants
that directly affect) our outcomes of interest or its determinants.
More speciﬁcally, data from the International HapMap Project show
that the SNPs that replicate in a large number of independent sam-
ples for educational attainment (Rietveld et al., 2013) and blood
pressure (Ehret et al., 2011) are not in LD with those for fat mass
(Speliotes et al., 2010).
Fourth, for canalization to violate the exclusion restriction, the
presence of the fat related variant at conception would have to
result in different brain or blood vessel development in order to
counter any predicted adverse effect of fat mass on the outcome.
We believe this is implausible. Furthermore, there is no evidence in
humans that canalization occurs in relation to complex traits such
as fat mass.
In summary, we  do not know individuals’ behavioural response
to their genotype, the speciﬁc physiological functions or biological
pathways through which the variants affect the phenotype, and
whether the variants have multiple phenotypic effects. With that,
it is impossible to guarantee that Assumption 2, exclusion, holds.
For instance, it is possible that some variants’ pleiotropic effects
7 The associations with hyperactivity, impulsivity, and inattention were not repli-
cable in independent samples. For more information, see the Web  Appendix.
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Table  2
Mean and standard deviation (SD) of adiposity for each SNP.
Gene rs number Adiposity-increasing/other
allele
Homozygous for Adiposity
non-increasing allele
Heterozygous Homozygous for
adiposity-increasing allele
Mean SD Mean SD Mean SD
NRXN3 rs10150332 C/T 99.7 9.69 100.0 9.81 101.1 10.49
BDNF  rs10767664 A/T 99.6 10.43 99.4 9.31 100.1 9.94
GNPDA2 rs10938397 G/A 99.5 10.02 99.9 9.70 100.3 9.53
LRRN6C rs10968576 G/A 99.9 9.89 99.8 9.67 99.8 9.66
PRKD1 rs11847697 T/C 99.7 9.68 100.9 10.66 99.4 6.81
GPRC5B rs12444979 C/T 98.6 8.71 99.9 9.65 99.9 9.84
CADM2 rs13078807 G/A 99.6 9.61 100.3 10.01 99.6 10.27
SLC39A8 rs13107325 T/C 99.8 9.73 100.2 10.10 100.2 7.61
TNNI3 K rs1514175 A/G 99.7 9.75 99.7 9.51 100.5 10.44
PTBP2 rs1555543 C/A 99.5 9.67 100.0 9.89 99.7 9.65
FTO  rs1558902 A/T 98.9 9.28 100.1 10.00 101.0 9.95
NUDT3 rs206936 G/A 100.0 9.77 99.4 9.70 100.0 10.31
FLJ35779 rs2112347 T/G 99.3 9.82 99.9 9.75 99.9 9.78
MAP2K5 rs2241423 G/A 99.6 9.89 99.9 10.00 99.8 9.63
QPCTL rs2287019 C/T 99.3 8.72 100.0 9.89 99.8 9.77
NEGR1 rs2815752 A/G 99.2 9.11 100.1 9.92 99.7 9.86
TMEM18 rs2867125 C/T 98.0 9.12 99.3 9.43 100.1 9.92
LRP1B rs2890652 C/T 99.7 9.64 100.1 10.02 99.8 10.54
KCTD15 rs29941 G/A 98.9 9.73 99.8 9.67 100.1 9.86
TMEM160 rs3810291 A/G 99.3 10.48 99.6 9.60 100.2 9.79
MTCH2 rs3817334 T/C 99.7 9.64 99.5 9.63 101.0 10.38
MTIF3 rs4771122 G/A 99.8 9.81 100.0 9.82 99.3 8.98
ZNF608 rs4836133 A/C 100.2 10.01 99.7 9.64 99.8 9.78
RPL27A rs4929949 C/T 99.6 9.52 100.0 9.88 99.8 9.76
SEC16B rs543874 G/A 99.5 9.55 100.3 9.99 101.5 10.86
MC4R  rs571312 A/C 99.4 9.42 100.3 10.11 101.1 10.94
RBJ  rs713586 C/T 99.1 9.98 99.8 9.63 100.7 9.76
FAIM2 rs7138803 A/G 99.6 9.67 99.9 9.87 100.6 9.72
SH2B1 rs7359397 T/C 99.6 9.70 99.8 9.83 100.2 9.76
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individual SNPs, the 64 alleles, and a weighted allelic score.FANCL rs887912 T/C 10
ETV5  rs9816226 T/A 9
TFAP2B rs987237 G/A 9
ave simply not yet been identiﬁed, or that there are other variants
hat are in LD with our instruments that affect the outcomes of
nterest, but have not yet been identiﬁed. Hence, similar to any
ther IV approach, exclusion remains an assumption, as we  cannot
est for this directly.
ssumption 3 (Non-zero effect of the instrument on treatment).  The
rior ﬁndings of robust associations between the genetic variants
nd fat mass, replicated in a large number of studies, justify their
se as instruments. Using standard statistical tests, we will examine
he strength of our instruments in the application below.
ssumption 4 (Monotonicity).  Finally, with random allocation of
enetic variants and the fact that individuals do not know their
enotypes, we assume that an individual who carries the risk allele
s at least as heavy as the same individual, had she not carried the
isk allele, satisfying monotonicity. Although we do not observe
ndividuals’ counterfactuals, the literature tells us that, at a group or
opulation level, those who possess the genetic variants are heavier
han those who do not.
As monotonicity can be violated by gene–environment inter-
ctions, we examine this in two ways. First, we explore the issue
f such interactions indirectly, testing whether the association
etween fat mass and our instrument differs in different ‘environ-
ents’. Although one can never observe all potentially relevant
ene–environment interactions, we explore the importance of a
et of environments that have been shown to be important for
hild development, deﬁned by gender, the child’s birth weight,
reastfeeding duration, social class, mother’s education, income
nd deprivation. The results (presented in Table S3 in the Web
ppendix) show little evidence of gene–environment interactions.
Second, we study the existing literature on gene–environment
nteractions for fat mass. Kilpelainen et al. (2011) ﬁnd some9.66 99.7 9.93 99.8 9.71
8.58 99.6 9.87 100.0 9.77
9.74 99.9 9.81 101.1 9.98
evidence of such interactions between FTO and physical activ-
ity, though only for adults: for the physically active, the FTO risk
allele increases the odds of obesity less than for the physically
inactive. They do not ﬁnd such interaction for children. Using a
sample of around 170,000 individuals, a recent study explores
whether genetic variants explain the variance of BMI  (as opposed to
the mean, as gene–environment interactions by construction lead
to variance inﬂation). They conclude that there are no common
genetic variants that account for a large proportion of variation
in environmental or phenotypic variability, ﬁnding no evidence of
widespread gene–environment interaction effects for BMI  (Yang
et al., 2012).
3.4. Descriptive statistics
Table 2 presents the mean adiposity for each of the 32 SNPs,
distinguishing between those who are homozygous for the adi-
posity non-increasing allele, heterozygous, and homozygous for
the adiposity-increasing allele. This shows that each of the indi-
vidual SNPs explain little of the variation in adiposity, leading to
low power in the IV analysis. Rather than using each of the individ-
ual SNPs, we therefore use an allelic score, deﬁned as the count of
the number of adiposity-increasing alleles. As we show below, this
explains a larger proportion of the variance in adiposity than the
individual SNPs, increasing the power of the instrument. In the sen-
sitivity analyses (Section 3.6), however, we also show the results
using different speciﬁcations of the instrument, including the 32Fig. 1 shows a histogram of the number of adiposity-increasing
alleles carried by each child, showing a bell-shaped distribution.
On average, children carry 29 adiposity-increasing alleles (standard
deviation = 3.4), with the total number ranging between 14 and 42.
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.5. Results
Table 3 presents the results. Panel A, columns 1 to 3 show the
ssociation between fat mass and the KS3 score, systolic, and dia-
tolic blood pressure, conditional on the 10 principal components.
he relationship between fat mass and educational attainment is
egative, with a one standard deviation increase in fat mass associ-
ted with a 0.09 standard deviation decrease in test scores. Columns
 and 3 show a positive association for blood pressure, with a one
tandard deviation increase in fat mass associated with a 0.23 and
.12 mmHg  increase in systolic and diastolic blood pressure respec-
ively; similar to approximately 0.02 of a standard deviation.
Panel B presents the ﬁrst-stage regression results, showing a
trong positive relationship between the instrument and child fat
ass. The strength of the relationship is shown by the ﬁrst stage
-statistic. A value of 76 (KS3) and 69 (blood pressure) suggests the
nstrument is strong. Translating the effect size into body weight, a
ne standard deviation increase in the allelic score increases weight
y around 1.3 to 1.5 kg, though the exact amount will depend on
hich alleles are carried by the individual, as there is much het-
rogeneity in the variants’ effect sizes on adiposity. For example,
ach risk allele of FTO – the variant that has been shown to have
he largest effect size – increases body weight by approximately
 kg for an average 11 year old, whereas the effect size for GNPDA2
ncreases body weight by just over 300 g.
able 3
LS and IV estimates of the average response in standardized KS3, systolic and diastolic b
Dependent variable (1) KS3 
Coeff p-Value 
Panel A: OLS
Fat mass coefﬁcient and p-value −0.092 <0.001 
95%  conﬁdence interval [−0.118, −0.065] 
Panel  B: First stage IV
Unweighted allelic score 0.349 <0.001 
95%  conﬁdence interval [0.270, 0.428] 
Panel  C: Second stage IV
Fat mass coefﬁcient and p-value 0.114 0.301 
95%  conﬁdence interval [−0.102, 0.331] 
First  stage F-statistic 75.47 
IV:  p-value, Hausman test 0.054 
Number of observations 4844 
otes: Column 1, 2 and 3 show the results, where the outcome variable is KS3, systolic and
rincipal components. 95% conﬁdence intervals in square brackets; p-value is the p-valueEconomics 45 (2016) 131–148
The second stage IV results are presented in Panel C. Colum 1
shows no effects of fat mass on educational performance. Although
the IV estimate is of similar magnitude but opposite sign to that in
Panel A, the large standard errors preclude us from rejecting the
null of no effect. However, with a p-value of 0.054 for the Hausman
test, there is some support for the IV as opposed to the OLS estimate,
though any such judgement should be based on a synthesis of all
the evidence, rather than on this one test alone.
Column 2 and 3 show a positive effect of fat mass on both systolic
and diastolic blood pressure, with an estimate that is somewhat
larger than the OLS estimates in Panel A. The estimates suggest
that a one standard deviation increase in fat mass increases systolic
and diastolic blood pressure by 0.37 and 0.21 mmHg  respectively,
though the Hausman test suggests that there is insufﬁcient evi-
dence to reject the hypothesis that the OLS estimate is unbiased.
3.6. Sensitivity analyses
We  next report a set of sensitivity analyses, evaluating the
robustness of the results. First, we use different speciﬁcations of
the instrument. We  start by specifying the 28 mutually exclu-
sive instruments, indicating the number of adiposity-increasing
alleles carried by each child. Panel A of Table 4 presents the results,
showing no effect of adiposity on KS3, but a positive effect on
both systolic and diastolic blood pressure. The over-identiﬁcation
(Hansen J) test does not reject the null. However, as discussed
above, it is difﬁcult to interpret this in a heterogeneous treatment
effects framework, as a rejection may  simply point to treatment
effect heterogeneity.
Panel B of Table 4 uses the 32 independent genetic variants
as 32 instrumental variables. Panel C speciﬁes the number of
adiposity-increasing alleles for each variant as separate instru-
ments (i.e. 64 instruments), and Panel D uses a weighted allelic
score. The latter is similar to the count of the number of risk
alleles, but incorporates the fact that the variants have different
effect sizes. Indeed, although the bias properties of the unweighted
score have been shown to be robust to mis-speciﬁcation (e.g. due
to mis-measurement of weights, gene–gene or gene–environment
interactions), it leads to a loss of power. We therefore use a
weighted allelic score, where the weights at each locus are deﬁnedpendent meta-analysis (Speliotes et al., 2010). Despite the different
instrument speciﬁcations and their strength in the ﬁrst stage as
shown by the F-statistic, the results are similar.
lood pressure.
(2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value
0.227 <0.001 0.116 <0.001
[0.188, 0.266] [0.088, 0.144]
0.365 <0.001 0.365 <0.001
[0.279, 0.451] [0.279, 0.451]
0.373 0.006 0.205 0.041
[0.105, 0.642] [0.009, 0.402]
68.78 68.78
0.276 0.365
4047 4047
 diastolic blood pressure, respectively. All analyses control for ancestry-informative
 for standard t-ratio.
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Table  4
IV robustness analyses: different speciﬁcations of the instrument.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Mutually exclusive instruments
Coefﬁcient and p-value 0.039 0.695 0.299 0.015 0.205 0.026
95%  conﬁdence interval [−0.16, 0.23] [0.06, 0.54] [0.03, 0.39]
First  stage F-statistic 8.90 8.20 8.20
IV:  p-value, Hausman test 0.183 0.962 0.482
IV:  p-value, Hansen J-test 0.862 0.574 0.531
Panel  B: 32 independent SNPs
Coefﬁcient and p-value −0.035 0.643 0.354 <0.001 0.093 0.195
95%  conﬁdence interval [−0.18, 0.11] [0.16, 0.54] [−0.05, 0.23]
First  stage F-statistic 4.93 4.38 4.38
IV:  p-value, Hausman test 0.508 0.176 0.859
IV:  p-value, Hansen J-test 0.039 0.594 0.602
Panel  C: No. of adiposity-increasing alleles for
each of the 32 SNPs
Coefﬁcient and p-value −0.031 0.647 0.372 <0.001 0.168 0.011
95%  conﬁdence interval [−0.16, 0.10] [0.20, 0.55] [0.04, 0.30]
First  stage F-statistic 3.11 2.63 2.63
IV:  p-value, Hausman test 0.277 0.082 0.267
IV:  p-value, Hansen J-test 0.422 0.531 0.144
Panel  D: Weighted allelic score
Coefﬁcient and p-value 0.080 0.370 0.452 <0.001 0.174 0.038
95%  conﬁdence interval [−0.10, 0.26] [0.23, 0.68] [0.01, 0.34]
First  stage F-statistic 116.7 101.3 101.3
IV:  p-value, Hausman test 0.049 0.045 0.482
IV:  p-value, Hansen J-test – – –
Panel  E: Selected instruments in weighted
score
Coefﬁcient and p-value 0.116 0.239 0.542 <0.001 0.182 0.037
95%  conﬁdence interval [−0.08, 0.31] [0.30, 0.78] [0.01, 0.35]
First  stage F-statistic 96.59 91.68 91.68
IV:  p-value, Hausman test 0.029 0.444 0.444
IV:  p-value, Hansen J-test – – –
Panel  F: Using only FTO and MC4R
Coefﬁcient and p-value 0.139 0.312 0.666 <0.001 0.230 0.082
95%  conﬁdence interval [−0.13, 0.41] [0.30, 1.03] [−0.03, 0.49]
First  stage F-statistic 24.54 21.81 21.81
IV:  p-value, Hausman test 0.078 0.011 0.340
IV:  p-value, Hansen J-test 0.403 0.192 0.147
Number of observations 4844 4047 4047
Notes: See notes to Table 3. Panel A shows the IV estimate using the mutually exclusive instrumental variables, indicating the number of adiposity-increasing alleles carried
by  each child. Panel B uses the 32 independent SNPs as 32 instruments. Panel C speciﬁes the number of adiposity-increasing alleles for each SNP as separate instruments
(i.e.  64 instruments). Panel D uses a weighted allelic score, where the weights at each locus are deﬁned by the effect size of the variant on adiposity, as estimated in an
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s  p-value for standard t-ratio.
As discussed in section 3.3, some of the variants in our analyses
ave been shown to associate with other, non-adiposity related,
henotypes, such as asthma and schizophrenia. In Panel E, we re-
stimate the IV model with the weighted IV score that drops these
ariants (see Web  Appendix) from the instrument set. In addition,
anel F shows the estimates using only FTO and MC4R,  the two
ariants that account for the largest proportion of the variation in
at mass, as the instrumental variables. The estimates are similar,
uggesting that the ﬁndings are not sensitive to the deﬁnition and
peciﬁcation of the instruments8.
Second, we explore the potential problem of weak instruments
n more detail, using the critical values in Stock and Yogo (2005).
lthough the weighted and unweighted allelic scores show strong
rst stage results, the F-statistic of approximately 8, 4 and 3 in
anels A, B and C of Table 4 respectively, imply that the rel-
tive bias of the IV estimates is between 10% and 20% (Panel
8 The results in Panel E and F that use a restricted instrument set are also robust to
sing an unweighted score, or using the variants/alleles separately as instruments.mative principal components. 95% conﬁdence intervals in square brackets; p-value
A) and over 30% (Panels B and C), and the size distortion over
25%. We  therefore compare these estimates to different estima-
tors that suffer less from weak instrument bias, using LIML and
Fuller-k (with k = 1). The critical values in Stock and Yogo (2005)
show that, for example, with 27 instruments and a ﬁrst stage F-
statistic of 8.3, the size distortion in LIML is less than 10%, and
Fuller has a relative bias that is less than 5%. We  present the
LIML and Fuller (1) results for our speciﬁcation with the largest
number of instruments (i.e. 64 instruments, as in Panel C of
Table 4) in Table 5, showing similar estimates for the different
estimators, suggesting that our results are not driven by weak
instruments.
Third, we explore different deﬁnitions of the variable of inter-
est: fat mass. As we  discuss in the introduction, obese children
may  have different educational outcomes due to sleep disorders,
school absenteeism, or differential treatment by teachers, parents
and peers. This would suggest that there may  be non-linearities.
Hence, it is of interest to study whether there are substantially
different effects on education and blood pressure for underweight
and overweight children. We  examine the child’s underweight and
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Table 5
IV robustness analyses: LIML and Fuller(1).
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: LIML
Fat mass coefﬁcient and p-value −0.001 0.991 0.477 0.002 0.216 0.084
95%  conﬁdence interval [−0.196, 0.194] [0.179, 0.775] [−0.029, 0.462]
First  stage F-statistic 3.11 2.63 2.63
p-value, Hausman test 0.277 0.082 0.267
p-value, Hansen J-test 0.434 0.608 0.156
Panel B: Fuller(1)
Coefﬁcient and p-value −0.002 0.985 0.474 0.002 0.215 0.082
95%  conﬁdence interval [−0.195, 0.192] [0.180, 0.769] [−0.027, 0.458]
First  stage F-statistic 3.11 2.63 2.63
p-value, Hausman test 0.277 0.082 0.267
p-value, Hansen J-test 0.433 0.605 0.156
Number of observations 4844 4047 4047
Notes: The models include 64 instruments, indicating whether the child carries each of the adiposity-increasing alleles for each SNP (as in Panel C of Table 4). All analyses
control for ancestry-informative principal components. See also notes to Table 3.
Table 6
IV robustness analyses: different speciﬁcations of the variable of interest.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Pr(Underweight)
Coefﬁcient and p-value −5.861 0.315 −19.26 0.021 −10.56 0.065
95%  conﬁdence interval [−17.3, 5.6] [−35.66, −2.85] [−21.77, 0.64]
First  stage F-statistic 19.91 18.22 18.22
p-value, Hausman test 0.205 0.012 0.060
Panel  B: Pr(Overweight)
Coefﬁcient and p-value 3.916 0.310 13.31 0.009 7.117 0.044
95%  conﬁdence interval [−3.64, 11.47] [3.46, 22.49] [0.21, 14.03]
First stage F-statistic 45.49 40.24 40.24
p-value, Hausman test 0.106 0.139 0.242
Number of observations 4844 4047 4047
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rotes: See notes to Table 3. Panel A presents the estimates for the effect of being un
verweight status in the IV analysis, deﬁned as being in the bottom
nd top 15th percentile of the fat mass distribution respectively.
e show the results using the (unweighted) allelic score as our
nstrumental variable, though they are robust to using the different
nstrument speciﬁcations. The results are presented in Table 6, with
anel A showing the estimates of being underweight, and panel B
resenting the effects for being overweight. These show that the
nstruments are somewhat less predictive of both binary indica-
ors. However, with a ﬁrst stage F-statistic ranging between 18 and
5, it is sufﬁciently strong, and the results show a similar pattern to
hose above. For Key Stage 3 (column 1), their imprecision means
e cannot reject the null of no effect. For blood pressure (columns 2
nd 3), the estimates conﬁrm that being underweight substantially
ecreases both systolic and diastolic blood pressure, whilst being
verweight leads to an increase.
Next, we explore the existence of heterogeneous effects of fat
ass on KS3 and blood pressure by gender. It may  be, for example,
hat girls are more affected by potential peers’ differential treat-
ent related to their adiposity than boys. Table 7, Panels A and B,
resent the results, showing a larger (positive) effect of adiposity
n educational attainment for girls than boys, though both remain
nsigniﬁcantly different from zero. We also ﬁnd an increase in sys-
olic blood pressure for both boys and girls, though no signiﬁcant
ffect on diastolic blood pressure for boys. Although we  are not the
rst to ﬁnd such gender differences (see e.g. Doll et al., 2002), the
easons for the differential effects by gender are unknown, witheight; Panel B shows the estimates for being overweight.
some suggesting it may  be due to gender differences in the body
fat distribution (Janssen et al., 2004).
Finally, we  examine the robustness of the estimates to the
inclusion of different sets of covariates. As we  argue in Section
2.4, our main analysis does not control for any covariates other
than the 10 principal components, as any covariates are mea-
sured post-randomization and, with that, may  be affected by the
treatment or outcome. However, one could argue that some covari-
ates are determined prior to, or at the time of, conception, such
as child gender and some parental characteristics. Controlling for
these covariates may  therefore increase the precision of the esti-
mates. Table 8 presents the results controlling for the child’s gender
(Panel A), for gender, maternal educational attainment, paternal
social class, and the Index of Multiple Deprivation, measured at
birth (Panel B), and for the full set of background characteristics
mentioned in Appendix B (Panel C). We  specify the (unweighted)
allelic score as the instrumental variable. All ﬁndings are simi-
lar to the initial estimates: the large standard errors mean we
cannot reject the null of no effect on the Key Stage 3 outcome,
but we  ﬁnd strong positive effects on blood pressure. The con-
ﬁdence interval becomes slightly narrower when we control for
the full set of characteristics, but it does not affect the inter-
pretation of the ﬁndings. Taken together, these analyses show
no evidence that children’s fat mass affects their academic per-
formance, but that increased fat mass leads to a rise in blood
pressure.
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Table  7
IV robustness analyses: subgroup analysis.
Dependent variable (1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Girls
Coefﬁcient and p-value 0.243 0.106 0.426 0.035 0.447 0.004
95%  conﬁdence interval [−0.05, 0.54] [0.03, 0.82] [0.14, 0.75]
First  stage F-statistic 43.43 33.65 33.65
p-value, Hausman test 0.008 0.263 0.020
Number of observations 2469 2089 2089
Panel B: Boys
Coefﬁcient and p-value −0.029 0.866 0.329 0.088 −0.043 0.767
95%  conﬁdence interval [−0.37, 0.31] [−0.05, 0.71] [−0.33, 0.24]
First  stage F-statistic 32.62 34.51 34.51
p-value, Hausman test 0.736 0.738 0.228
Number of observations 2375 1958 1958
Notes: See notes to Table 3. Panels A and B present the estimates for girls and boys respectively.
Table 8
IV robustness analyses: controlling for covariates.
(1) KS3 (2) Systolic blood pressure (3) Diastolic blood pressure
Coeff p-Value Coeff p-Value Coeff p-Value
Panel A: Covariates: gender
Fat mass coefﬁcient and p-value 0.111 0.319 0.379 0.006 0.206 0.042
95%  conﬁdence interval [−0.11, 0.33] [0.11, 0.65] [0.01, 0.40]
First  stage F-statistic 77.18 69.51 69.51
p-value, Hausman test 0.044 0.288 0.371
Panel  B: Covariates: gender, maternal
education, social class at birth, IMD
Fat mass coefﬁcient and p-value 0.092 0.342 0.379 0.007 0.206 0.046
95%  conﬁdence interval [−0.10, 0.28] [0.10, 0.66] [0.00, 0.41]
First  stage F-statistic 79.61 68.61 68.61
p-value, Hausman test 0.122 0.288 0.363
Panel  C: Covariates: all1
Fat mass coefﬁcient and p-value 0.090 0.322 0.374 0.008 0.201 0.052
95%  conﬁdence interval [−0.09, 0.27] [0.10, 0.65] [−0.00, 0.40]
First  stage F-statistic 81.56 69.35 69.35
p-value, Hausman test 0.156 0.284 0.382
N  4844 4047 4047
Notes: See notes to Table 3. All analyses control for ancestry-informative principal components.
1 All covariates includes: child birth weight, age at KS3 (in months), ln(income), mother’s educational attainment, a binary indicator whether the child was  raised by the
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fatural  father, social class at birth, dummy variables indicating whether the mother
eprivation (IMD, measured at birth), binary variables indicating whether the moth
he  duration of breastfeeding, and mother’s age at birth. The deﬁnition of the covar
. Conclusion and discussion
Economists have become increasingly interested in the effects
f behaviours such as smoking, drinking or excessive food intake on
conomic outcomes. As these behaviours are endogenous and dif-
cult (if not impossible) to randomize in an RCT, estimating their
ffects is difﬁcult. Many studies therefore attempt to ﬁnd instru-
ental variables, or exploit some natural experiment that shifts
he behaviour for some group, but not others, to identify their
ausal impact. The increasing availability of biomedical data, in
ombination with a growing medical literature on the effects of
arrying speciﬁc genetic variants, introduces a different approach
o the examination of certain risk factors on different outcomes.
his paper discusses the method of instrumental variables using
endelian randomization, and links this to the statistical potential
utcomes framework. Mendelian randomization provides a novel
pproach to estimating the causal impact, and with that will be of
nterest to economists to explore.We  note that its suitability and applicability depends on a set
f (biological) conditions, as well as on the research question and
ontext. We  discuss the speciﬁc conditions that need to be met
or genetic variants to be used as instruments, and relate these to part-time or full-time, and whether the partner is employed, the Index of Multiple
ank alcohol during pregnancy, and whether the mother smoked during pregnancy,
s given in the note to Table B1, Appendix B.
the statistical assumptions necessary for identiﬁcation of the aver-
age causal response using instrumental variables. These conditions
have not been well deﬁned in the current social science litera-
ture, but understanding them is crucial to the appropriate use of
genotypes as instruments for modiﬁable risk factors.
We review these conditions in the context of two  empirical
applications. First, we  examine whether child fat mass causally
affects academic achievement, and second, we  study whether it
affects blood pressure. To study the effect of adiposity on our
outcomes of interest, a well-conducted RCT would randomize an
intervention that reduces fat mass and compare the outcomes
between the group that was  treated and the control group. Ran-
domizing adiposity, however, is difﬁcult. We show that, in such
cases, quasi-experimental designs such as Mendelian randomiza-
tion experiments can provide an interesting alternative approach.
We  use a set of 32 recently identiﬁed genetic variants as instru-
mental variables for fat mass to illustrate the key concepts. In these
illustrative examples, we  show the systematic approach required to
identify genetic variants as instruments. We  also use direct meas-
ures of fat mass, rather than the generally used BMI. OLS  shows
that leaner children perform better in school tests compared to
their fatter counterparts, and that fatter children have higher blood
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ressure. Our genetic IV analysis, however, shows no evidence that
hildren’s fat mass affects their academic performance, whilst we
nd that fat mass increases children’s blood pressure.
Our discussion of the conditions for the suitability of genetic
ariants as instrumental variables and our application raise some
ore general issues of the use of genetic variants as instruments.
irst is the question whether genetic variants are powerful enough
o identify causal effects. In the illustrative case we examine, while
ur instruments are not weak in a statistical sense their effects may
e too small to impact on the possible pathways to academic per-
ormance. In other words, a 1–2 kg increase in fat mass may  not
ead to a large drop in self-esteem or an increase in absenteeism.
t is, therefore, perhaps not surprising that we ﬁnd no signiﬁcant
ffect on academic performance. In contrast, our results on blood
ressure show strong evidence of an increase driven by elevated
at mass. As intervention studies of weight reduction (see e.g. the
eta-analysis of randomized controlled trials by Neter et al., 2003)
ave shown that a 5 kg weight loss is sufﬁcient to cause a reduc-
ion in systolic blood pressure of about 4 mmHg, this suggests that
ven small changes in fat mass, such as those driven by genetic
ariants,can identify changes in blood pressure with sufﬁcient pre-
ision (see also Timpson et al., 2009).
Hence, if small changes in the risk factor are sufﬁcient to shift the
utcome of interest, Mendelian randomization presents an inter-
sting approach. However, if the outcome of interest is only affected
y large changes in the risk factor, Mendelian randomization may
ot be sufﬁciently powerful, as genetic variants generally shift the
isk factor by a relatively small amount. This is particularly relevant
or studies in economics, which are often interested in the effects of
ifferent intermediate phenotypes (e.g. adiposity, smoking, drink-
ng) on economic outcomes. In contrast to various examples in the
edical literature, ﬁnding effects on such economic outcomes gen-
rally requires larger changes in the risk factor. With most genetic
ariants having small effect sizes, this suggests they explain insuf-
cient variation in the risk factor to affect the outcome of interest.
ith a rapidly growing medical literature on the effects of carry-
ng speciﬁc variants, one option is to wait for more variants to be
dentiﬁed and to combine these into one a (weighted) count of the
umber of risk alleles. This could increase the explained phenotypic
ariation and with that, the precision of the estimates. But for the
ype of physical attributes that economists have been interested in
uch as fat mass or height, any additional variants are likely to have
ven smaller effects than those already identiﬁed9.
A second issue is the credibility of the IV assumptions. Some of
hese are testable, but others are not. In particular, the validity of
he exclusion restriction cannot be tested, and will never be known
ith certainty, which makes Mendelian randomization a contro-
ersial approach within the economics literature. Our paper has
iscussed this in detail and highlighted the various ways through
hich the use of genetic variants as instrumental variables may
ead to invalid inferences. With our limited understanding of the
unctions of variants and the pathways through which they affect
utcomes, it is unlikely that we will understand their exact func-
ion and mechanism in the foreseeable future. Hence, we  argue
hat genetic variants need to be used with care. Their appropriate
se requires that several conditions, which have not hitherto been
pelt out in the economics literature, are met. However, even if
hese conditions are met, the sample sizes in data sets that contain
oth genetic markers and outcomes of interest to economists may
e too small to obtain deﬁnitive results. Indeed, even with around
000–5000 observations, our standard errors are relatively large.
9 For example, the most recent (at time of writing) GWAS identiﬁed an additional
6  BMI-associated loci, which generally have lower minor allele frequency and/or
maller effect size estimates than previously known loci (Locke et al., 2015).Economics 45 (2016) 131–148
But with a rapid increase in the number of genome wide associa-
tion studies, and with a decrease in their costs, this may  change.
Finally, just as there are good and poor RCTs and studies using any
other identiﬁcation design and methodology, there are good and
poor Mendelian randomization studies. By highlighting the poten-
tial problems and showing the systematic approach required to
identify genetic variants as instruments, we  attempt to steer oth-
ers to carefully consider the different assumptions and conditions
needed for valid inference before jumping to their use.
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Appendix A. A brief introduction to genetics
Each cell in the human body contains a nucleus in which most
DNA (99.9995%) is kept. DNA is stored in structures called chromo-
somes, where each chromosome contains a single continuous piece
of DNA. All cells in the human body apart from germ cells contain
46 chromosomes, organized into 23 chromosome pairs: one copy of
chromosome 1–22 from each parent, plus an X-chromosome from
the mother and either an X or a Y chromosome from the father.
Locations (or loci) where DNA varies between people are
called polymorphisms. The most commonly studied form of poly-
morphism is a Single Nucleotide Polymorphism (SNP): a single
base-pair variation in a DNA locus. As chromosomes come in pairs,
humans have two base-pairs at each locus, called alleles. These
alleles can either be the same or different. The term genotype is
used to describe the speciﬁc set of alleles inherited at a particular
chromosome locus. For example, individuals can have one of three
genotypes of FTO: they can be homozygous for the common allele
(TT), heterozygous (AT), and homozygous for the rare allele of FTO
(AA). The visible or measurable effect of a particular genotype is
called the phenotype. The phenotype, or risk factor, we examine is
fat mass.
Many studies have examined the heritability of fat mass, deﬁned
as the proportion of the total variance that is explained by genetic
factors. These are most commonly calculated from twin studies,
comparing intra-pair correlations for a characteristic in monozy-
gotic twins with that in dizygotic twins. These studies generally
report large heritability estimates: between 0.4 and 0.7. A high heri-
tability however, does not imply that any individual genetic variant
has large phenotypic effects. For example, there are many SNPs
that affect human weight, though all with small effects: so-called
‘polygenes’. Together, these variants may  have a large phenotypic
effect.
Until recently, researchers mainly used a ‘candidate gene
approach’ to examine associations between individual genetic vari-
ants and a risk factor. This approach consists of testing a speciﬁc
hypothesis: based on biological knowledge, researchers exam-
ine the association between one particular variant (the candidate
genetic variant) and a risk factor. These studies produced many
false-positive ﬁndings (Colhoun et al., 2003) and were inefﬁcient.
Genome wide association studies (GWAS) followed, genotyping
500,000 to over 1,000,000 SNPs in one go and relating all SNPs to
the risk factorof interest in a hypothesis-free way. Stringent criteria
are used for GWAS p-values to take account of this hypothesis-free
approach. Studies are either two-stage studies, where one or more
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Table  B1
An indirect test of independence: regressing the covariate on the instruments.
Unweighted allelic score Weighted allelic score 32 independent variants
Coefﬁcient Standard error Coefﬁcient Standard error p-Value of F-test:
instrument-coefﬁcients jointly
equal to zero
Girl 0.00 (0.00) 0.00 (0.01) 0.560
Birth  weight (g) 2.62 (2.18) 19.22 (14.11) 0.550
Age  at KS3 (in months) 0.04*** (0.02) 0.16 (0.10) 0.341
Ln(income) 0.00 (0.00) 0.00 (0.01) 0.392
Mother’s education −0.00 (0.00) −0.00 (0.02) 0.341
Raised by natural father 0.00 (0.00) 0.00 (0.01) 0.731
Social class at birth −0.00 (0.01) −0.03 (0.03) 0.076
Mum  works part-time 0.00 (0.00) −0.01 (0.01) 0.971
Mum  works full-time −0.00 (0.00) −0.00 (0.01) 0.428
Partner employed 0.00 (0.00) 0.01 (0.01) 0.905
Index  of Multiple Deprivation −0.06 (0.06) 0.32 (0.37) 0.259
Alcohol during pregnancy 0.00 (0.00) 0.01 (0.01) 0.596
Smoke during pregnancy 0.00 (0.00) 0.00 (0.01) 0.697
Breastfeeding 0.00 (0.00) 0.00 (0.03) 0.080
Mother’s age at birth 0.00 (0.00) −0.00 (0.02) 0.076
*** p < 0.01; The p-value in the last column corresponds to an F-test of the coefﬁcients on the 32 instrumental variables jointly equalling zero; Ln(income) is measured when
the  child is aged 3–4 as is in 1995 prices; mother’s educational level is a categorical variable with four values (less than ordinary (O) level, O-level, advanced (A) level, and
university degree); social class is measured using the standard UK classiﬁcation of class based on occupation (professional (I), managerial and technical (II), non-manual skilled
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BIIInm), manual skilled (IIIm), semi-skilled (IV) and unskilled (V)); the Index of Mult
o  areas containing about 8000 persons; breastfeeding is a categorical variable (nev
WAS is performed, after which the small number of SNPs that
each GWAS levels of statistical signiﬁcance are typed in other inde-
endent samples to examine the robustness. Alternatively, studies
onsist of a number of independent GWAS containing a large total
ample size, where only those SNPs that have consistent associa-
ions across all studies are interpreted as robust.
ppendix B. Indirect test of independence of covariates and
enetic variants
Table B1 presents the coefﬁcients (standard errors) of a regres-
ion of the covariate in the ﬁrst column on the unweighted allelic
core (columns 1 and 2) or weighted allelic score (columns 3 and 4).
he ﬁnal column shows the p-value of an F-statistic testing whether
he coefﬁcients on the 32 independent variants jointly equal zero.
ith random assignment of the genetic variants, there should be
o systematic variation in the covariates by genotype. Although
ome coefﬁcients are signiﬁcantly different from zero, there is no
vidence of systematic differences for the different covariates, pro-
iding at least suggestive evidence of randomization of genetic
ariants.
ppendix C. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.jhealeco.2015.10.
07.
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